EVALUATING TREATMENT RESPONSE, SURVIVAL OF STAGE IV NON SMALL CELL LUNG CANCER BY PEMETREXED – CARBOPLATIN REGIMEN

Khánh Toàn Nguyễn1, Thị Hường Phạm1,, Xuân Hạnh Cấn2, Văn Nhật Nguyễn3
1 Oncology Hospital Nghe An
2 National lung hospital
3 Nghe An Oncology Hospital

Main Article Content

Abstract

Aims: To evaluate response and survival of patients with stage IV Non small cell lung cancer who were treated by Pemetrexed – Carboplatin regimen. Patients and method of study: Retrospective and prospective study on 45 non-small cell lung cancer patients in stage IV treated by Pemetrexed - Carboplatin regimen  from August 2018 to August 2021. Results: Median of age 59,2 ± 7,4, male/female: 5,4/1. 39/45 (89,7%) patients completed four cycles, and 30/45 (66,7%) completed six cycles of chemotherapy. Objective response rate is 37,8%; disease control rate is 66,7%. Performance status and age are factors affecting response rate. The mean progression-free survival (PFS) was 7.4 ± 0.3 months, the median PFS was 7.7 months. The mean overall survival (OS) was 20.5 ± 1.9 months, the median OS was 19 months. Conclusion: Pemetrexed- Carboplatin regimen is effective in the treatment of stage IV non small cell lung cancer.

Article Details

References

1. Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. May 2021;71(3):209-249. doi:10.3322/caac.21660
2. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. Dec 1 2005;104(11):2449-56. doi:10.1002/cncr.21480
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Jul 20 2008;26(21):3543-51. doi:10.1200/jco.2007.15.0375
4. Ito M, Horita N. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis. Apr 2019;15(2):e3-e10. doi:10.1111/ ajco.12837
5. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute. Jun 6 2007;99(11):847-57. doi:10.1093/jnci/djk196
6. Wang W, Shang L, Li X, Li J, Wen F, Liu J. [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. Jan 2011; 14 (1):54-7. doi:10.3779/j.issn.1009-3419. 2011.01.11
7. Trần Thanh Hà. Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng phác đồ pemetrexed – carboplatin tại bệnh viện K. Trường Đại học Y Hà Nội; 2018.
8. Katirtzoglou N, Gkiozos I, Makrilia N, et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clinical lung cancer. Jan 2010;11(1):30-5. doi:10.3816/ CLC.2010.n.005